McDermott Advises the Nov Santé Actions Non Cotées fund managed by Eurazeo on its investment in Horus Pharma
McDermott Will & Emery has advised the Nov Santé Actions Non Cotées fund, which is managed by Eurazeo and is dedicated to the development of healthcare in France, on its investment in Horus Pharma, a French pharmaceutical company specializing in ophthalmology.
With this investment in Horus Pharma, the Nov Santé Actions Non Cotées fund concludes its fourth operation, following on from the acquisition of stakes in the Novair, PSIH and Seqens groups. One year after its launch, nearly a quarter of the fund has now been deployed to accelerate the development and transformation of healthcare in France.
Horus Pharma is a major player in ophthalmology in France and is entering a new phase of growth, built around 3 pillars: R&D, the marketing of innovative products and the internationalization of the company.
The managers had chosen the Nov Santé Actions Non Cotées fund to partner with due to its broad expertise in the healthcare sector.
The McDermott team that advised Nov Santé Actions Non Cotées comprised :
Diana Hund, partner and Boris Wolkoff, associate, on corporate aspects;
Anne-France Moreau, partner, and Raphaëlle Monjou, associate, on Life Sciences aspects;
Pierre-Arnoux Mayoly, partner and Stanislas Chenu, counsel, on financing aspects;
Antoine Vergnat, partner, Côme de Saint-Vincent, counsel and Fanny Le Pogam, associate, on tax aspects.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.